Warfarin Dosing in a Patient with CYP2C9*3*3 and VKORC1-1639 AA Genotypes
Genetic factors most correlated with warfarin dose requirements are variations in the genes encoding the enzymes cytochrome P450 2C9 (CYP2C9) and vitamin K epoxide reductase (VKOR). Patients receiving warfarin who possess one or more genetic variations in CYP2C9 and VKORC1 are at increased risk of a...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2014-01-01
|
| Series: | Case Reports in Genetics |
| Online Access: | http://dx.doi.org/10.1155/2014/413743 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832549793028636672 |
|---|---|
| author | Mark Johnson Craig Richard Renee Bogdan Robert Kidd |
| author_facet | Mark Johnson Craig Richard Renee Bogdan Robert Kidd |
| author_sort | Mark Johnson |
| collection | DOAJ |
| description | Genetic factors most correlated with warfarin dose requirements are variations in the genes encoding the enzymes cytochrome P450 2C9 (CYP2C9) and vitamin K epoxide reductase (VKOR). Patients receiving warfarin who possess one or more genetic variations in CYP2C9 and VKORC1 are at increased risk of adverse drug events and require significant dose reductions to achieve a therapeutic international normalized ratio (INR). A 74-year-old white female with atrial fibrillation was initiated on a warfarin dose of 2 mg PO daily, which resulted in multiple elevated INR measurements and three clinically significant hemorrhagic events and four vitamin K antidote treatments over a period of less than two weeks. Genetic analysis later revealed that she had the homozygous variant genotypes of CYP2C9*3*3 and VKORC1-1639 AA. Warfarin dosing was subsequently restarted and stabilized at 0.5 mg PO daily with therapeutic INRs. This is the first case report of a white female with these genotypes stabilized on warfarin, and it highlights the value of pharmacogenetic testing prior to the initiation of warfarin therapy to maximize efficacy and minimize the risk of adverse drug events. |
| format | Article |
| id | doaj-art-5519f0c5487d486ea0c3989419127636 |
| institution | Kabale University |
| issn | 2090-6544 2090-6552 |
| language | English |
| publishDate | 2014-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Case Reports in Genetics |
| spelling | doaj-art-5519f0c5487d486ea0c39894191276362025-02-03T06:08:31ZengWileyCase Reports in Genetics2090-65442090-65522014-01-01201410.1155/2014/413743413743Warfarin Dosing in a Patient with CYP2C9*3*3 and VKORC1-1639 AA GenotypesMark Johnson0Craig Richard1Renee Bogdan2Robert Kidd3Bernard J. Dunn School of Pharmacy, Shenandoah University, Winchester, VA 22601, USABernard J. Dunn School of Pharmacy, Shenandoah University, Winchester, VA 22601, USAPinnacleHealth, Harrisburg, PA 17109, USABernard J. Dunn School of Pharmacy, Shenandoah University, Winchester, VA 22601, USAGenetic factors most correlated with warfarin dose requirements are variations in the genes encoding the enzymes cytochrome P450 2C9 (CYP2C9) and vitamin K epoxide reductase (VKOR). Patients receiving warfarin who possess one or more genetic variations in CYP2C9 and VKORC1 are at increased risk of adverse drug events and require significant dose reductions to achieve a therapeutic international normalized ratio (INR). A 74-year-old white female with atrial fibrillation was initiated on a warfarin dose of 2 mg PO daily, which resulted in multiple elevated INR measurements and three clinically significant hemorrhagic events and four vitamin K antidote treatments over a period of less than two weeks. Genetic analysis later revealed that she had the homozygous variant genotypes of CYP2C9*3*3 and VKORC1-1639 AA. Warfarin dosing was subsequently restarted and stabilized at 0.5 mg PO daily with therapeutic INRs. This is the first case report of a white female with these genotypes stabilized on warfarin, and it highlights the value of pharmacogenetic testing prior to the initiation of warfarin therapy to maximize efficacy and minimize the risk of adverse drug events.http://dx.doi.org/10.1155/2014/413743 |
| spellingShingle | Mark Johnson Craig Richard Renee Bogdan Robert Kidd Warfarin Dosing in a Patient with CYP2C9*3*3 and VKORC1-1639 AA Genotypes Case Reports in Genetics |
| title | Warfarin Dosing in a Patient with CYP2C9*3*3 and VKORC1-1639 AA Genotypes |
| title_full | Warfarin Dosing in a Patient with CYP2C9*3*3 and VKORC1-1639 AA Genotypes |
| title_fullStr | Warfarin Dosing in a Patient with CYP2C9*3*3 and VKORC1-1639 AA Genotypes |
| title_full_unstemmed | Warfarin Dosing in a Patient with CYP2C9*3*3 and VKORC1-1639 AA Genotypes |
| title_short | Warfarin Dosing in a Patient with CYP2C9*3*3 and VKORC1-1639 AA Genotypes |
| title_sort | warfarin dosing in a patient with cyp2c9 3 3 and vkorc1 1639 aa genotypes |
| url | http://dx.doi.org/10.1155/2014/413743 |
| work_keys_str_mv | AT markjohnson warfarindosinginapatientwithcyp2c933andvkorc11639aagenotypes AT craigrichard warfarindosinginapatientwithcyp2c933andvkorc11639aagenotypes AT reneebogdan warfarindosinginapatientwithcyp2c933andvkorc11639aagenotypes AT robertkidd warfarindosinginapatientwithcyp2c933andvkorc11639aagenotypes |